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Computational Investigation of 
Homologous Recombination DNA 
Repair Deficiency in Sporadic 
Breast Cancer
Yue Wang1,2, Matthew H. Ung2, Sharon Cantor3 & Chao Cheng2,4,5
BRCAness has important implications in the management and treatment of patients with breast and 
ovarian cancer. In this study, we propose a computational framework to measure the BRCAness of 
breast and ovarian tumor samples based on their gene expression profiles. We define a characteristic 
profile for BRCAness by comparing gene expression differences between BRCA1/2 mutant familial 
tumors and sporadic breast cancer tumors while adjusting for relevant clinical factors. With this 
BRCAness profile, our framework calculates sample-specific BRCA scores, which indicates homologous 
recombination (HR)-mediated DNA repair pathway activity of samples. We found that in sporadic 
breast cancer high BRCAness score is associated with aberrant copy number of HR genes rather than 
somatic mutation and other genomic features. Moreover, we observed significant correlations of BRCA 
score with genome instability and neoadjuvant chemotherapy. More importantly, BRCA score provides 
significant prognostic value in both breast and ovarian cancers after considering established clinical 
variables. In summary, the inferred BRCAness from our framework can be used as a robust biomarker 
for the prediction of prognosis and treatment response in breast and ovarian cancers.
Breast cancer is the most common type of cancer in female patients, with one out of eight women developing 
breast cancer in their lifetime1. Many factors have been found to be associated with the increased risk of this dis-
ease including family history2. Familial breast cancer represents a minor percentage of all breast cancer cases and 
can occur in patients with one or more closely related family members diagnosed with breast, ovarian, or related 
cancer2,3. Approximately 25% of familial breast cancer cases may be attributed to germline mutations in two 
major breast cancer susceptibility genes, BRCA14 and BRCA25. Germline mutations in BRCA1 and BRCA2 genes 
exhibit high penetrance and confer a 60–80% and 40–85% lifetime risk of developing breast cancer, respectively6. 
In ovarian cancer, BRCA1 and BRCA2 germline mutations will confer a risk of 40–60% and 30%, respectively7. 
Other than germline mutations in these two genes, many other genetic mutations or variants can contribute to 
familial breast cancer including germline mutations with high (e.g., TP53 and PTEN) and low penetrance (e.g., 
ATM and BRIP1), as well as low-penetrance genetic variants (e.g., single-nucleotide polymorphisms (SNPs))8.
BRCA1 and BRCA2 are essential regulators of the homologous recombination (HR) pathway that are involved 
in the repair of double-stranded DNA breaks9,10. HR-dependent DNA repair restores damaged DNA sequences 
to its original state without introducing DNA mutations. When this pathway is inactivated, e.g., as a result of 
BRCA1/2 mutations, alternative DNA repair pathways such as non-homologous end joining (NHEJ) become 
the major pathways utilized for repairing double-strand DNA breaks. These alternative repair mechanisms are 
error-prone and lead to rapid accumulation of somatic mutations which increase the risk of carcinogenesis11,12. 
Interestingly, somatic mutations in BRCA1/2 are rarely observed in sporadic breast cancers13,14. However, defects 
in HR-dependent DNA repair can arise through other mechanisms, resulting in a “BRCA-like” phenotype. For 
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this reason, the concept of “BRCAness” has been introduced to describe this shared phenotype between sporadic 
cancers and familial cancers with BRCA1/2 mutations15,16.
BRCAness has important implications in the management and treatment of patients with sporadic breast 
and ovarian cancer15–18. It has been shown that tumors with defects in the HR-dependent DNA repair pathway 
are hypersensitive to alkylating, platinum-based chemotherapies that generate DNA interstrand crosslinks and 
induce double-stranded DNA breaks during crosslink removal19,20. However, tumors with deficient BRCA1 activ-
ity are not sensitive to mitotic spindle poisons such as the taxanes and vincristine21. This is because that spindle 
disruption caused by these agents can induce apoptotic cell death in BRCA-proficient but not in BRCA-deficient 
tumors. It has been shown that downregulation of BRCA1 gene expression in ovarian cancer cell lines increases 
their sensitivity to platinum treatment but leads to resistance to antimicrotubule agents22,23. In addition, tumors 
with deficient BRCA1/2 are also sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors as a result of syn-
thetic lethality24,25. In particular, PARP is involved in another DNA repair pathway called base excision repair 
(BER) that repair single-strand DNA breaks26. Inhibition of PARP results in accumulation of DNA single-strand 
breaks, replication fork collapse and double-strand DNA repair that are lethal in tumors with deficient HR 
pathway.
The hallmarks of BRCAness are elevated genomic instability and deficient HR pathway activity. Accordingly, 
there are two strategies to determine the BRCAness of sporadic breast tumor samples. The first strategy is to clas-
sify BRCA-like and non-BRCA-like samples based on copy number variation (CNV) data. Classification mod-
els have been constructed by selecting genomic regions with differential CNV between familial (with BRCA1/2 
germline mutations) and sporadic breast cancer samples, and then applying these models to assess BRCAness in 
sporadic samples27. These methods assume that there exist ‘hot’ genomic regions with recurrent CNV shared by 
the majority of BRCA-deficient familial and BRCA-like sporadic samples. However, this assumption may not hold 
when considering the high heterogeneity of sporadic tumors. The second strategy is to define gene signatures that 
characterize HR deficiency and apply them to identify HR-deficient sporadic tumor samples. Konstantinopoulos 
et al.28 defined a BRCAness gene signature by comparing transcriptomic profiles between BRCA1/2 mutant and 
sporadic ovarian tumor samples, and applied it to classify sporadic ovarian tumors. Their approach demonstrated 
that samples with high levels of BRCAness were associated with improved survival. A related approach involves 
generating BRCAness gene expression profiles from breast cancer cell line with RNA-mediated inactivation of 
HR pathway genes (e.g. BRCA1, RAD51 and BRIT1)29. However, our previous study using this approach showed 
that the resulting gene expression profiles from these knockdown cell line were more likely to reflect the reduced 
proliferation of cells rather than HR deficiency30.
In this study, we propose a robust statistical framework to characterize a BRCAness gene expression profile 
to interrogate BRCA activity in sporadic breast cancer samples. The BRCAness profile is generated by compar-
ing gene expression between BRCA1/2 mutant familial tumors with sporadic breast tumors. In addition, this 
statistical model used to define the profile takes into account clinical factors that could explain differences in 
gene expression, thus effectively isolating the expression changes most likely to be induced by varying levels of 
BRCAness. This characteristic BRCAness profile utilizes all genes rather than a gene signature composed of a 
selected group of genes to achieve robust statistical performance. Application of this framework to The Cancer 
Genome Atlas (TCGA) breast cancer omics data revealed high heterogeneity of BRCAness mechanisms in spo-
radic breast cancer. Our results indicate that in sporadic breast cancer, copy number variation (CNV), especially 
deletions, contributes more to the inactivation of HR pathway compared to somatic mutations, DNA methylation, 
and expression changes in BRCA-like samples. Other than BRCA1/2, CNV in other HR genes play a more impor-
tant role to reduce HR pathway activity in sporadic breast tumors. We also identified several other HR pathway 
genes with CNV associated with BRCAness, suggesting that other members of the axis may contribute more to 
HR pathway activity. Moreover, the inferred BRCA score is predictive of clinical outcomes of patients with breast 
cancer, providing a potential prognostic marker. In addition, this BRCAness profile, although being defined for 
breast cancer, is also applicable to ovarian cancer.
Results
Schematic overview of our study. Our computational framework starts by comparing familial breast 
tumors carrying either BRCA1 or BRCA2 mutations with sporadic cancer samples to generate a BRCAness char-
acteristic profile (Fig. 1). This comparison adjusts for several clinical factors including age, grade, tumor size, 
estrogen receptor (ER) status, and Human Epidermal Growth Factor Receptor 2 (HER2) status to ensure that the 
BRCAness characteristic profile reflects BRCA1/2 mutation status rather than differences in the distribution of 
these clinical variables across patients. Given a tumor gene expression dataset, this BRCAness profile calculates a 
sample-specific BRCA score for each individual patient in the dataset by using the BASE algorithm, which meas-
ures the similarity between a patient’s tumor expression profile and the BRCAness profile31. Patients with higher 
BRCA scores are more similar to have BRCA1/2 germline mutations in terms of their expression profiles, and 
thereby more likely to have defective HR pathway activity.
Defining characteristic weight profiles that encode BRCAness. We utilized the data generated by 
Larsen et al.32 to define three BRCAness characteristic profiles (denoted as BRCA1-, BRCA2- and BRCA1/2-based 
profiles) by respectively comparing BRCA1-, BRCA2- or BRCA1/2-mutant (both BRCA1 and BRCA2) famil-
ial samples with sporadic samples. In a BRCAness profile, each gene was assigned a weight based on the dif-
ference in expression it exhibits between BRCA1/2-mutated familial from sporadic breast cancer samples. 
Namely, genes with high weights were significantly up- or down-regulated in BRCA1/2-mutated samples after 
adjusting for several clinical variables that may be potential confounders. We selected 300 genes with the high-
est positive (up-regulated in BRCA1/2-mutant) and 300 genes with the highest negative (down-regulated in 
BRCA1/2-mutant) weights in the BRCAness profile and identified the enriched biological pathways. Our results 
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indicate that cell cycle associated and DNA replication pathways are significantly enriched in the up-regulated 
genes (Supplementary Table S1). In addition, the same analyses were performed using top weighted genes in 
BRCAness profiles defined based on BRCA1 versus sporadic and BRCA2 versus sporadic profiles and obtained 
similar results. These results are consistent with the known functions of BRCA1 and BRCA2 (Supplementary 
Table S1).
Calculated BRCA score discriminates familial from sporadic breast tumors. We then examined 
whether BRCA score could distinguish familial breast cancer patients from sporadic patients. Because the Larsen 
et al. dataset32 was utilized to define three BRCAness characteristic profiles, we first compared their performance 
using this dataset. We calculated sample-specific BRCA scores for the 33 BRCA1-mutant familial samples, the 
22 BRCA2-mutant familial samples, and the 128 sporadic samples using the BRCA1, BRCA2 and the BRCA1/2- 
profiles, respectively (Fig. 2a). We found that BRCA1-mutant (Mann-Whitney Wilcoxon test P = 6e-13) and 
BRCA2-mutant (Mann-Whitney Wilcoxon test P = 6e-4) familial samples have significantly higher BRCA 
scores than sporadic samples when using all three BRCAness profiles (Fig. 2a). To further evaluate the predic-
tive accuracy of the BRCA score, we trained a binary classification model to classify familial breast tumors from 
sporadic tumors (Fig. 2b). When using the BRCA1-based profile, the calculated BRCA scores could clearly dis-
criminate familial BRCA1-mutant tumors from sporadic ones with an area under the curve (AUC) 0.901 (Fig. 2b, 
left). Similarly, the BRCA scores were able to distinguish familial BRCA2-mutant tumors from sporadic ones 
(AUC = 0.718), and all familial BRCA1/2-mutant tumors from sporadic ones (AUC = 0.828). Consistent obser-
vations were showed in the classifications utilizing the BRCA2-based (Fig. 2b, middle) and the BRCA1/2-based 
(Fig. 2b, right) BRCAness profiles. These results indicate that the calculated BRCA score can distinguish familial 
breast cancer patients from sporadic ones with high accuracy and can capture differences in the BRCAness phe-
notype. A high BRCA score implies high likelihood of carrying a BRCA1/2 germline mutation and thus a more 
deficient HR pathway. Notably, the calculated BRCA scores using the BRCA1/2-based profile achieved the best 
classification accuracy when comparing familial breast tumors from sporadic ones (Fig. 2b, right, AUC = 0.861 
for BRCA1 vs. sporadic, ACU = 0.809 for BRCA2 vs. sporadic and AUC = 0.84 for BRCA1/2 vs. sporadic). Based 
on these results, we applied the BRCA scores calculated using the BRCA1/2-based profile for subsequent analyses.
Moreover, we utilized the GSE5056733 dataset to further test the ability of the BRCA score to classify breast 
cancer patients. This dataset contained 12 BRCA1- and 1 BRCA2-mutated hereditary breast tumors, 8 BRCAx 
(non-BRCA1/2 mutations, donated as non-BRCA) hereditary breast tumors, 14 sporadic breast cancer sam-
ples and 6 normal samples. However, we found that 5 sporadic and 1 BRCAx samples had methylated BRCA1 
promoters which could result in transcriptional silencing of BRCA134 and a reduction in HR pathway activity. 
Figure 1. Overview of our computational framework. In short, we first compared the gene expression profiles 
between familial and sporadic breast tumors considering related clinical factors (e.g. age, grade, tumor size, ER 
status and Her2 status) to generate a BRCAness profile. Second, by integrating gene expressions of given breast 
cancer samples, we calculated sample-specific BRCA scores. The scores inferred the BRCAness of patients 
with the higher score the higher likelihood to be BRCAness. Then, we showed that the BRCA score classifies 
familial from sporadic breast tumors, correlates with genomic instability, predicts patients’ survival and predicts 
chemotherapy response. Lastly, we further applied the BRCAness profile defined with breast cancer profiles to 
ovarian cancer. The corresponding BRCA scores also can classify familial from sporadic samples and predict 
prognosis.
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Therefore, we combined these 6 patients with the 12 BRCA1- and 1 BRCA2-mutated hereditary breast cancer 
patients into one group (donated as “BRCA”). The comparison of BRCA scores showed that patients in the BRCA 
group have higher BRCA scores than normal breast samples (Fig. 2c, Mann-Whitney Wilcoxon test P = 6e-06) 
Figure 2. BRCA score classifies familial from sporadic breast cancer patients. (a) Boxplot for comparisons of 
BRCA scores in germline mutate-BRCA1 (green box), germline mutate-BRCA2 (tawny box) and sporadic (blue 
box) breast cancer samples using gene expression of germline mutate-BRCA1 (left), germline mutate-BRCA2 
(middle), germline mutate-BRCA1/2 (both BRCA1 and BRCA2, right) as reference to compare with those of 
sporadic ones, respectively. Mann-Whitney Wilcoxon test P-values were calculated to show the differences of 
BRCA scores between germline mutate-BRCA1 and sporadic breast cancer samples, germline mutate-BRCA2 
and sporadic breast cancer samples. (b) ROC curves for the accuracy of classifying familial from sporadic 
breast cancer patients using BRCA scores calculated by comparing gene expression of germline mutate-BRCA1 
(left), germline mutate-BRCA2 (middle), germline mutate-BRCA1/2 (right) as reference to sporadic ones, 
respectively. Black curve: comparison of patients with germline BRCA1 mutations to sporadic ones. Magenta 
curve: comparison of patients with germline BRCA2 mutations to sporadic ones. Cyan curve: comparison of 
patients with germline BRCA1 and BRCA2 mutations to sporadic ones. AUC scores were shown. The BRCA 
scores calculated based on germline BRCA1/2 mutations achieved the best AUCs. (c) Boxplot for BRCA scores 
calculated by integrating BRCAness profile and gene expression profile offered by GSE50567 which contains 
profiles for familial BRCA1 and BRCA2 (BRCA), other familial with non-BRCA mutations, sporadic and normal 
breast cancer samples. Whitney Wilcoxon test P-values were listed. (d) Same with (c) but for GSE27830 which 
contains profiles for four familial breast cancer samples including BRCA1, BRCA2, CHEK2 and other mutations 
(non-mutations of aforementioned genes). (e) Same with (c) but for GSE19177 which contains profiles for three 
groups of familial breast cancer samples including BRCA1, BRCA2 and non-BRCA1/2 mutations.
www.nature.com/scientificreports/
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and sporadic tumors (Mann-Whitney Wilcoxon test P = 0.04). Moreover, patients carrying BRCA mutations 
had higher BRCA scores than the other familial tumors with non-BRCA mutations (Mann-Whitney Wilcoxon 
test P = 7e-04). Furthermore, we observed similar results in two additional familial breast cancer datasets. The 
GSE2783035–37 dataset provided gene expression profiles for 155 familial primary breast cancer samples includ-
ing 47 BRCA1-, 6 BRCA2-, 26 CHEK2- mutant samples and 76 samples without mutations in these three genes. 
Due to the limited number of BRCA2-mutant patients, we merged BRCA1- and BRCA2-mutant patients into 
one group. Based on the BRCA1/2-based profile, we calculated BRCA scores to patients in this dataset and 
found that patients with BRCA1/2 mutations have significantly higher BRCA scores than those with CHEK2 
(Mann-Whitney Wilcoxon test P = 2e-05) and other gene (Mann-Whitney Wilcoxon test P = 6e-05) mutations 
(Fig. 2d). We found similar results in the GSE19177 dataset38,39 which contains expression profiles for 19 BRCA1, 
30 BRCA2 and 25 non-BRCA1/2 mutation familial breast cancer samples (Fig. 2e). Again, patients with BRCA1 
mutations had higher BRCA scores than those with non-BRCA1/2 mutations. These observations suggest that 
the calculated BRCA score is an effective classifier to distinguish familial breast tumors from sporadic tumors 
and to identify BRCA1 or BRCA2 mutated patients within familial breast cancer patients. The score is negatively 
correlated with the deficient HR pathway activity caused by BRCA1 or BRCA2 mutation.
Association of BRCA score with genomic features. Because BRCAness significantly correlates with 
genomic instability15, we extended our computational framework to TCGA breast cancer datasets to further exam-
ine the correlation of BRCA score with genomic features. First, we investigated the association between BRCA 
score and somatic mutations. By comparing the difference in BRCA score between mutated and non-mutated 
samples for each gene, we found that somatic mutation status of three genes, TP53 (Mann-Whitney-Wilcoxon 
Test P = 2e-30), PIK3CA (Mann-Whitney-Wilcoxon Test P = 1e-16) and CHD1 (Mann-Whitney-Wilcoxon Test 
P = 2e-17), were significantly correlated with the BRCA score. Specifically, patients with higher BRCA scores were 
more likely to carry TP53 mutations (Supplementary Fig. S1). In contrast, patients with lower BRCA scores were 
more likely to harbor mutated PIK3CA and CHD1 (Supplementary Fig. S1). Then, we examined the overall asso-
ciation between BRCA score and CNV in breast cancer samples. According to TCGA CNV dataset, we divided 
genes into deletion (CNV < 1.2), normal and duplication (CNV > 2.8) groups. Ranking TCGA patients based 
on their BRCA scores, we found that high BRCA scores correlate with CNV (Supplementary Fig. S1). Last, by 
calculating the z scores across CpG sites for each patient, we found that BRCA scores are overall associated with 
DNA methylation (Supplementary Fig. S1).
Then, we compared the BRCA scores of TCGA breast cancer samples with their CNV burden and mutation 
burden, respectively. We observed that patients with a higher BRCA score had higher CNV burden (Fig. 3a, 
r = 0.624) and higher mutation burden (Fig. 3b, r = 0.409). These results imply that the BRCA scores are positively 
correlated with genomic instability. This might be because a high BRCA score indicates a defective HR DNA 
repair pathway which can result in a more abnormal genome. Since BRCA scores infer HR pathway activity, we 
next focused on 27 HR genes defined by the KEGG database40 to reveal the correlation between BRCA score and 
their genomic features. First, we ranked TCGA breast cancer patients based on their BRCA scores in a decreas-
ing order. Second, we compared differences in CNV, DNA methylation, and gene expression of the 27 HR genes 
between top ranked patients (top 1% to 20%) and low ranked patients (remaining patients) (See Methods). We 
observed that patients with higher BRCA scores exhibited significant copy number deletion (CNV < 1.2) of the 27 
HR genes compared to those with lower scores (Fig. 3c). In contrast, we observed no significant changes in DNA 
methylation or gene expression of the 27 HR genes between top ranking and low ranking patients. These results 
suggest that CNV is the primary driver of HR pathway inactivation, while DNA methylation and gene expression 
play minor roles in determining pathway activity. Moreover, we compared the BRCA scores for patients with 27 
HR genes copy number deletion (CNV < 1.2) to the rest patients. Higher BRCA scores were observed in patients 
with deletion compared to the others (Fig. 3d, Mann-Whitney-Wilcoxon Test P = 9e-12). When only focusing 
on the two key pathway genes, BRCA1 and BRCA2, we observed that copy number deleted patients have higher 
BRCA scores (Fig. 3d, Mann-Whitney-Wilcoxon Test P = 7e-04). However, the p-value for comparison using 
BRCA1 and BRCA2 was lower than that using the 27 HR genes which suggests that the deletion of other HR path-
way genes might contribute more to effect HR pathway activity (Fig. 3d). In addition to CNV, we observed con-
sistent results when comparing somatic mutation status with BRCA score. Namely, patients with mutations in the 
27 HR genes (n = 68) exhibited higher BRCA scores compared to patients without a mutation in either of the 27 
HR genes (Fig. 3e, Mann-Whitney-Wilcoxon Test P = 0.02). Moreover, patients with mutated BRCA1 or BRCA2 
(n = 25) exhibited higher BRCA scores compared to non-mutant samples (Fig. 3e, Mann-Whitney-Wilcoxon 
Test P = 0.006).
BRCA score predicts breast cancer patient prognosis. We next sought to evaluate whether the BRCA 
score could predict survival outcomes of breast cancer patients. First, we calculated the BRCA scores using our 
method for patients from the METABRIC cohort, which provides the most comprehensive breast cancer gene 
expression dataset that is accompanied by exhaustive clinical records for 1,992 primary breast cancer patients41. 
We next compared the association of BRCA scores with clinic pathological characteristics including grade and 
stage which are well-established clinical indicators of disease severity. Our results show that the calculated BRCA 
score was positively correlated with tumor grade, with higher grade tumors showing higher BRCA scores (Mann–
Whitney U-test, P = 3e-88; Fig. 4a). Likewise, we observed that patients with stage 2–4 tumors exhibited signifi-
cantly higher BRCA scores compared to patients with stage 1 tumors (Mann–Whitney U-test, P = 2e-05; Fig. 4b). 
These results indicate that BRCA score reflects the aggressiveness of tumors and can serve as an indicator of 
disease progression.
Moreover, we ranked the BRCA scores of patients from high to low and analyzed the distribution of patients 
based on several variables including TP53 mutation, ER status, progesterone receptor (PR) status, HER2 
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Figure 3. BRCA score correlates with breast cancer genomic features. (a) Correlation between BRCA scores 
and CNV burden. Spearman correlation coefficient and corresponding P-value were listed. (b) Correlation 
between BRCA scores and log-10 transferred mutation burden. Spearman correlation coefficient and 
corresponding P-value were listed. (c) We ranked TCGA breast cancer patients based on their BRCA scores in 
a decreasing order. We then compared the difference between top ranked (from 1% to 20%) patients and the 
remaining according to CNV, DNA methylation and gene expression of the 27 HR genes. The differences were 
calculated through the Mann-Whitney-Wilcoxon Test. Negative log-10 transferred P-values were shown. (d) 
Boxplot for BRCA scores in patients with 27 HR genes deletions and scores in the rest patients. And Boxplot for 
BRCA scores in patients with only BRCA1 and BRCA2 deletions and scores in the rest patients. Mann-Whitney-
Wilcoxon Test P-values were listed. (e) Boxplot for BRCA scores in patients with 27 HR genes mutations and 
scores in the rest patients. And Boxplot for BRCA scores in patients with only BRCA1 and BRCA2 mutations 
and scores in the rest patients. Mann-Whitney-Wilcoxon Test P-values were listed.
www.nature.com/scientificreports/
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status, triple negative status, and molecular subtype (Fig. 4c and Supplementary Fig. S2). Patients carrying TP53 
mutations were tended to have higher BRCA scores compared to those with wild-type TP53 (Mann–Whitney 
Wilcoxon test P = 2e-12) which is consistent with our result in the TCGA dataset. Moreover, we found that 
ER+ patients have a higher likelihood of lower BRCA scores compared to those with ER− (Mann–Whitney 
Wilcoxon test P = 2e-34). Similar, PR+ patients had lower calculated BRCA scores than those with PR− (Mann–
Whitney Wilcoxon test P = 9e-31). In contrast, patients with HER2+ tended to have higher BRCA scores (Mann–
Whitney Wilcoxon test P = 5e-12). Moreover, triple negative breast cancer (TNBC) was more likely to be present 
in patients with high BRCA scores (Mann–Whitney Wilcoxon test P = 1e-28). Furthermore, we compared the 
BRCA scores in patients with Basal, HER2-enriched, Luminal A, Luminal B, or Normal-like tumors. Patients 
with higher BRCA scores had higher risk to be predicted as Basal-like (Mann–Whitney Wilcoxon test P = 2e-40), 
HER2-enriched (Mann–Whitney Wilcoxon test P = 3e-18) and Luminal B (Mann–Whitney Wilcoxon test 
P = 9e-50) breast cancers. However, patients with lower BRCA scores were more likely to be Luminal A (Mann–
Whitney Wilcoxon test P = 8e-91) and Normal-like (Mann–Whitney Wilcoxon test P = 4e-49) breast cancer. 
Additionally, normal-like breast cancer patients tend to have the lowest BRCA scores.
After demonstrating that BRCA scores vary across samples with different clinical features, we evaluated 
whether BRCA scores could predict breast cancer prognosis. Using BRCA score as the independent variable, we 
performed survival analyses in the METABRIC discovery and validation datasets. Namely we divided patients 
Figure 4. BRCA score predicts prognosis for breast cancer patients. (a) Boxplot for BRCA scores of patients in 
different grades. Mann–Whitney U-test P-value was listed. (b) Same as (a) but for different cancer stages. (c) 
Distribution of BRCA scores based on breast cancer subtypes. Then, we ranked the BRCA scores and showed 
the correlations with TP53 mutation, ER status, PR status, Her2 status, triple negative breast cancer (TNBC) and 
molecular breast cancer subtypes. We compared BRCA scores in TP53 mutation vs. TP53 wild type, ER+ vs. 
ER−, PR+ vs. PR−, Her2+ vs. Her2−, TNBC vs. the other breast cancer samples, Basal-like vs. non-Basal-like, 
HER2-Enriched vs. non-HER2-Enriched, Luminal A vs. non-Luminal A, Luminal B vs. non-Luminal B and 
Normal vs. non-Normal patients. P-values were calculated using Mann–Whitney Wilcoxon test. (d–g) Kaplan-
Meier plots for BRCA scores comparison of the (d) discovery, (e) validation datasets in the METABRIC dataset, 
(f) Ur-Rehman dataset, (g) Vijver dataset. Patients with low BRCA scores (green curve) had better survival than 
those with high BRCA scores (red curve). Hazard ratio (HR) and log-rank test P-value were shown.
www.nature.com/scientificreports/
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into high and low BRCAness categories by stratifying on median BRCA score. We observed that high BRCAness 
was associated with a significant increase in mortality risk in the discovery cohort (Fig. 4d, P = 2e-06) with a 
hazard ratio (HR) of 1.83. Similarly, this result was reproduced in the METABRIC validation dataset (Fig. 4e, 
P = 6e-07, HR = 1.92). In addition, we found that the BRCA score was predictive of prognosis in ER+ patients 
in both the discovery (HR = 1.63, P = 0.001) and validation (HR = 2.24, P = 1e-06) datasets, with BRCA score 
being associated with increased mortality risk (Supplementary Fig. S3). In ER− patients, exhibited lower prog-
nostic ability potentially due to high heterogeneity of ER− tumors42. Interestingly, we found that TNBC patients 
with high BRCA scores exhibited improved survival in the discovery dataset (Supplementary Fig. S4, HR = 2.21, 
P = 0.008).
To further evaluate the reproducibility of the BRCA score to predict survival, we applied the weight profiles 
to interrogate and perform survival analysis in two additional breast cancer datasets by Ur-Rehman et al.43 and 
Vijver et al.44. Our results remained consistent in that patients with high BRCA scores had worst prognosis than 
those with low BRCA scores (Ur-Rehman, Fig. 4f, P = 2e-06, HR = 1.68; Vijver, Fig. 4g, P = 2e-05, HR = 3.09). 
Additionally, the BRCA score was able to better predict mortality in patients with ER+ tumors compared to 
patients with ER− tumors in both datasets (Supplementary Fig. S4). Furthermore, to determine if the BRCA 
score could provide additional prognostic information to traditional clinicopathological variables, we fit-
ted a multivariate Cox regression model to the METABRIC dataset using BRCA scores and clinical variables 
including age, ER status, Her2 status, stage, and grade as independent variables. Our results show that BRCA 
scores (HR = 1.63, P = 3e-03) remain predictive to prognosis even after considering other clinical information 
(Supplementary Table S2).
BRCA score predicts patient response to neoadjuvant chemotherapy. Since BRCAness is a bio-
marker for responsiveness of chemotherapy15, we further examined whether the BRCA score could predict patient 
response to neoadjuvant chemotherapy. We calculated BRCA scores for patients in the Hatzis breast cancer data-
set, which includes treatment response information to neoadjuvant taxane-anthracycline chemotherapy for 508 
breast cancer samples45. BRCA scores were calculated with the BRCA1-, BRCA2- and BRCA1/2-based profiles, 
respectively. First, we used BRCA scores to classify patients achieving pathologic complete response (pCR) and 
those with residual disease (RD). The results showed that using the BRCA1-based profile to calculate BRCA 
scores (AUC = 0.74) achieves the best accuracy for classification compared to using the BRCA2- (AUC = 0.59) 
or BRCA1/2-based (0.66) profiles (Fig. 5a). Moreover, to demonstrate that the BRCA score contributes to clin-
icopathological variables in predicting treatment response, we constructed random forest models to classify pCR 
patients from patients with RD (Fig. 5b). For one model, we only used the clinical variables including age, ER 
status, PR status, HER2 status, grade, stage, node information as predictors. We compared this model to a second 
model where we include both BRCA scores and clinicopathological variables as predictors. We observed that 
BRCA scores calculated from the BRCA1-based profile yielded the highest average AUC (AUC = 0.73) compared 
to scores generated from there BRCA2- (AUC = 0.715) and BRCA1/2-based (AUC = 0.719) profiles. These results 
suggest that using the BRCA scores calculated using BRCA1-based BRCAness profiles achieve the best accuracy 
for classification which in line with the previously studies46,47. Therefore, we applied those BRCA1-based BRCA 
scores to the rest chemotherapy prediction.
Moreover, applying the BRCA scores calculated with BRCA1-based BRCAness profile, we found 
that pCR patients have higher BRCA scores than RD patients (Fig. 5c, Mann-Whitney-Wilcoxon Test 
P = 3e-06). In addition, we observed consistent results in different breast cancer subtypes. For patients with 
ER+ (Mann-Whitney-Wilcoxon Test P = 0.002), ER− (Mann-Whitney-Wilcoxon Test P = 0.002) and TNBC 
(Mann-Whitney-Wilcoxon Test P = 0.02), we entirely found that pCR patients have higher BRCA scores com-
pared to the RD patients (Supplementary Fig. S5). Moreover, we divided patients into low, intermediate, and high 
BRCA score groups and tested the fraction of pCR patients in each group. As shown in Fig. 5d, there were 5.9%, 
14.7% and 35.3% pCR patients in these 3 groups. Moreover, patients with the high BRCA scores were 6-fold 
more likely to be pCR compared to those with the low scores. These observations suggest that our BRCA score 
could be utilized as a biomarker which can predict the response to neoadjuvant chemotherapy. Therefore, BRCA 
score could apply to practical clinical application helping doctors to improve treatment decisions and prognosis 
determinations.
Apply the BRCAness characteristic profile to ovarian cancer. Previous studies have shown that 
BRCAness also plays an important role in ovarian cancer48,49. Briefly, due to the sensitivity of chemotherapy50, 
BRCAness is significantly associated with ovarian cancer outcome51. Thus, we evaluated whether the BRCAness 
characteristic profile generated using breast cancer profiles can be applied to interrogate pathway activity in ovar-
ian cancer. Using gene expression profiles from ovarian cancer tumor samples provided by Jazaeri et al.52, we 
first calculated sample-specific BRCA scores for each patient in the dataset using the BRCA1/2-based breast 
cancer profile. The Jazaeri dataset52 contained 18 germline BRCA1 mutated, 16 germline BRCA2 mutated 
and 27 sporadic ovarian cancer samples. By comparing the BRCA scores, we found that patients with BRCA1 
germline mutations have higher BRCA scores than either patients with BRCA2 germline mutations (Fig. 6a, 
Mann-Whitney-Wilcoxon Test P = 0.001) or sporadic ones (Mann-Whitney-Wilcoxon Test P = 7e-04) which 
are consistent with their results52. Moreover, using the BRCA score could classify BRCA1-mutated familial ovar-
ian cancer tumors from sporadic ones with high accuracy (AUC = 0.778). When classifying BRCA1 or BRCA2 
mutant samples from sporadic cancers we achieved an AUC = 0.660; however, classification of only germline 
BRCA2 mutant tumors was inaccurate (AUC = 0.528) (Fig. 6b). These observations suggest that the BRCA score 
using the BRCA1 profile can be applied as a prognostic biomarker in ovarian cancer.
Therefore, we tested whether the BRCA score could predict ovarian cancer prognosis using the Bonome et al.53, 
TCGA54 and the Yoshihara et al.55 datasets, which contain 185, 557, and 260 patients, respectively. After 
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calculating a BRCA score for each patient, we divided them into BRCA-like and non BRCA-like groups using 
median BRCA score as the cutoff. Interestingly, we observed that BRCA-like patients exhibited decreased mor-
tality risk in both the Bomone (Fig. 6c, HR = 0.67, P = 0.03) and TCGA datasets (Fig. 6d, HR = 0.68, P = 9e-04). 
A similar trend was observed using the Yoshihara dataset (Supplementary Fig. S6, HR = 0.9) but the difference 
between two groups was not significant (P > 0.05). These results were in line with the previous study28,56, which 
suggest the BRCAness profile calculated with breast cancer expression profiles can be applied to ovarian cancer.
Figure 5. BRCA score predicts chemotherapy for breast cancer samples. (a) ROC curves for the accuracy of 
classifying pathologic complete response (pCR) from residual disease (RD) breast cancer patients. The BRCA 
scores were calculated using gene expression of germline mutate-BRCA1 (red), germline mutate-BRCA2 (blue), 
germline mutate-BRCA1/2 (green) as reference to compare with those of sporadic ones, respectively. AUC 
scores were listed. (b) Barplot for the mean AUC scores of 10-fold cross validation using clinical information 
(gray), clinical information + BRCA1 based BRCA scores (C+B1, red), clinical information + BRCA2 based 
BRCA scores (C+B2, blue) and clinical information + BRCA1/2 based BRCA scores (C+B1/2, green) to classify 
pCR from RD patients. The corresponding average AUCs were listed above each bar. Standard deviations 
were plotted with the error bars. (c) Boxplot for BRCA scores in patients with pCR (dark orange) and RD 
(chardonnay). BRCA scores were calculated using the BRCA1-based profiles. Mann-Whitney-Wilcoxon Test 
P-value was listed. (d) Barplot for pCR patients’ fractions in different BRCA score groups. The chardonnay bar 
is RD patients and the dark orange bar is pCR patients. Corresponding pCR rate of each group were listed above 
the bars.
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Discussion
Our analyses indicate that BRCAness can be caused by different genomic mechanisms including somatic muta-
tions, aberrant methylation, deletions and downregulated expression of genes involved in DNA repair. It is 
notable that gene deletions might contribute more to BRCAness than other genomic changes in sporadic breast 
cancers (Fig. 3a). In line with this observation, we found that the BRCA score of samples is more correlated 
with CNV burden than with mutation burden (Fig. 3b,c). However, this observation may not justify the use of 
CNV-based supervised classification models to assess BRCAness27. Although BRCAness is associated with a high 
level of genome instability as manifested by high CNVs, genomic deletions or amplifications that occur may not 
exist in most BRCA-like samples to provide informative predictors for these classification models due to the het-
erogeneity of sporadic tumor samples–BRCAness can be caused by inactivating different genes via distinct mech-
anisms, such as DNA methylation and mutations. To address this shortcoming, we developed a framework that 
measures BRCAness based on transcriptomic profiles which capture the final downstream readout of genomic 
lesions that abrogate HR pathway activity. As such, a key question is why can the BRCAness profile be defined by 
comparing BRCA1/2-mutant familial tumor samples with sporadic samples? The familial breast tumor samples 
used for defining the BRCAness profile inherit a copy of defective BRCA1/2 gene, predispose them to breast 
Figure 6. BRCA scores implements in ovarian cancer. (a) Boxplot for BRCA scores in germline mutate-BRCA1, 
germline mutate-BRCA2 and sporadic ovarian cancer samples. Patients carrying germline BRCA1 mutations 
had much higher BRCA scores than sporadic ones (Mann-Whitney-Wilcoxon Test P = 7e-04). (b) ROC curves 
for the accuracy of classifying familial from sporadic ovarian cancer patients using BRCA scores. Black curve: 
comparison of patients with germline BRCA1 mutations to sporadic ones. Magenta curve: comparison of 
patients with germline BRCA2 mutations to sporadic ones. Cyan curve: comparison of patients with germline 
BRCA1 and BRCA2 mutations to sporadic ones. AUC scores were shown. (c) Kaplan-Meier plots for patients’ 
prognosis in the Bonome ovarian cancer dataset. BRCA-like patients (red curve) had better survival than non 
BRCA-like ones (green curve). Hazard ratio (HR) and log-rank test P-value were shown. (d) Same as (c) but for 
TCGA ovarian cancer samples.
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cancer when the function of the other allele is lost (again, this can be caused by different genomic mechanisms). 
Thus, the familial breast tumor samples carrying BRCA1/2 germline mutations represent a ‘homogenous’ set of 
cancers that are driven by HR pathway inactivation. As a result, it is possible to create a characteristic BRCAness 
gene expression profile that encodes the transcriptomic changes accoiated with known loss of HR pathway activ-
ity. Breast tumor’s HR pathway activity could be inferred via this profile where a high BRCA score that indicates 
low activity. Although the familial breast tumor samples provide an ideal positive dataset for defining BRCAness 
profile, the sporadic samples may not be a good negative dataset since some of these sporadic samples may be 
BRCA-like causing by other mechanisms such as BRCA1 promoter DNA methylation, deletions of other HR 
genes or post-transcriptional regulation. Thus, we would expect to further improve our analysis by excluding 
these BRCA-like samples to achieve a more accurate BRCAness profile.
In the TCGA breast cancer data, 13 and 14 samples contain at least one somatic mutation in BRCA1 and 
BRCA2, respectively. We mapped these mutations to the protein sequence of BRCA1 and BRCA2, and calculated 
the corresponding BRCA scores for these samples (Supplementary Fig. S7). The majority of these patients with 
BRCA1/2 somatic mutations are associated with positive BRCA scores, indicating lower HR pathway activities. 
However, nine out of 27 samples are associated with negative scores, suggesting that different mutation types in 
BRCA1 and BRCA2 genes vary in their functional impacts. To inactivate the HR pathway, both BRCA1/2 alleles 
have to be defective, which might occur through different mechanisms. Furthermore, it is often difficult to deter-
mine the effect of a particular mutation occurred in BRCA1/2 genes. Potentially, some mutated BRCA1/2 pro-
teins may preserve the ability to bind but cannot repair DNA, and furthermore, prevent the wild-type BRCA1/2 
(encoded by the other allele) from carrying out repairing functions, and therefore result in a dominant effect57,58 
posing another layer of complexity. Therefore, the BRCA scores calculated by our framework provide a useful 
measurement for BRCAness in sporadic breast cancer samples.
Our analyses indicate that the BRCAness profile defined based on familial breast cancer samples can be applied 
to classify BRCA1/2-mutant familial versus sporadic ovarian cancer. It can also be used to assess BRCAness in 
sporadic ovarian tumor samples that show significant correlation with prognosis of patients. This indicates shared 
gene expression patterns between breast and ovarian cancer with BRCAness phenotypes. Interestingly, BRCAness 
is associated with poor prognosis in breast cancer but good prognosis in ovarian cancer. This might be due to the 
difference of treatments for these two cancer types. For ovarian cancers, it has higher likelihood to be high-grade 
serous carcinoma (HGSC) when the cancer was investigated59. It has been confirmed that HGSC is sensitive to 
platinum-based chemotherapy60. This is consistent with our conclusion that a patient with high BRCA score 
(high BRCA score is similar to HGSC) is more responsive to chemotherapy (Fig. 5c,d). In contrast, breast cancer 
is mostly driven by ER61 which is generally treated by hormone therapy.
Methods
Datasets. We collected gene expression and clinical information for breast cancer and ovarian cancer patients 
from 13 datasets (Supplementary Table S3). Larsen et al.32 provided the gene expression for 55 familial and 128 
sporadic breast tumor samples. In the familial samples, 33 and 22 carry BRCA1 and BRCA2 germline mutations. 
We downloaded this data from the Gene Expression Omnibus (GEO) database with accession number GSE40115. 
The GSE5056733 contained 12 BRCA1- and 1 BRCA2-mutated hereditary breast tumors, 8 BRCAx (non-BRCA1/2 
mutations) hereditary breast tumors, 14 sporadic breast cancer samples and 6 normal samples. The GSE2783035–37 
dataset provided gene expression profiles for 155 familial primary breast cancer samples including 47 BRCA1-, 
6 BRCA2-, 26 CHEK2- mutant samples and 76 samples without mutations in these three genes. The GSE19177 
dataset38,39 contained expression profiles for 19 BRCA1, 30 BRCA2 and 25 non-BRCA1/2 mutation familial breast 
cancer samples. The METABRIC breast cancer dataset41 contained gene expression and exhaustive clinical profiles 
for 1,992 tumors which was downloaded from the European Genome Phenome Archive with accession number 
EGAS00000000083. The METABRIC dataset provided TP53 status for 820 patients including 99 patients with TP53 
mutations and 721 patients with wild type TP53. The Ur-Rehman dataset43 contained 1,170 samples integrated 
from 5 existed breast cancer datasets62–66 and was downloaded with accession number GSE47561. The Vijver data-
set44 was downloaded from the Netherlands Cancer Institute (http://ccb.nki.nl/data/) and contained gene expres-
sion and clinical profiles for 295 breast cancer patients. The Hatzis dataset45 contained the response to neoadjuvant 
chemotherapy for 508 HER2-negative breast cancer samples with an accession ID GSE25066. Additionally, we 
applied our analyses to three OV datasets. Jazaeri dataset52 contained 18 germline mutated BRCA1, 16 germline 
mutated BRCA2 and 27 sporadic ovarian cancer samples accessing with GSE82007. Bonome et al.53 provided 
the gene expression profile for 185 late-stage and high-grade ovarian cancer patients with the accession number 
GSE26712. Yoshihara et al.55 contained 260 Japanese advanced-stage ovarian cancer patients which was down-
loaded with an accession number GSE32062. Besides, additional TCGA datasets for breast cancer67 and ovarian 
cancer54 samples were collected from FIREHOSE Broad institute (https://gdac.broadinstitute.org/).
Define characteristic profiles for homologous recombination DNA repair pathway. The gene 
expression dataset generated by Larsen et al.32 was used to define the characteristic profile for BRCAness in breast 
cancer. This data was provided as log transformed expression at probeset level. We converted the data into gene 
expression data based on the probeset annotation. For genes with multiple probesets, the probeset with the high-
est average hybridization signals across all samples was selected to represent a gene.
Following that a logistic linear regression model was constructed for each gene to evaluate its power for differ-
entiating BRCA1/2-mutant samples from sporadic samples while adjusting several important clinical variables. 
Specifically, the following model is used:
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where pj is the probability of the sample j is BRCA1/2-mutant.
For each sample, the model calculated a coefficient and its p-value for each variable. The sign of β indicates 
whether genei has higher expression levels in familial (if β > 0) or sporadic (if β <= 0) samples. The p-value for β 
indicates the capability of the gene to discriminate familial from sporadic samples, the smaller p-value the more 
significant discriminative power. Logistic linear regression was performed for all genes and the resulting beta 
coefficients were collected into a vector Bj = {β1, β2,…, βn} and the p-values were collected into a vector Pj = {p1, 
p2, …, pn}, where n is the total number of genes. Based on the two vectors, a pair of weight profiles was generated 
to quantify the discriminative power of all genes to differentiate familial from sporadic samples using the follow-
ing functions:
β β= − ∗ > = − ∗ <= .+ −W p W pI Ilog 10( ) ( 0) and log10( ) ( 0)j ji i i i
This pair of weight profiles characterize up- (Wj+) and down-regulated (Wj−) genes in j-th familial sample, 
respectively. I is the indicator function which outputs 1 if β >= 0 and 0 when β <= 0. Weights greater than 10 in 
these profiles were trimmed to avoid extreme values. By integrating the weight profiles cross samples, we gener-
ated W+ and W− weight profiles, which, together, defines the characteristic profile for BRCAness. Based on the 
Larsen et al.32 dataset, we define three BRCAness profiles for breast cancer by comparing BRCA1, BRCA2 and 
BRCA1/2 familial samples with sporadic samples, respectively.
Calculate sample-specific activity score for homologous recombination DNA repair pathway. 
The BRCAness profile weights genes in a sorted tumor gene expression profile to discriminate HR-defective 
samples (familial) from HR-proficient samples (sporadic). Given this profile, we apply a rank-based method to 
infer HR pathway activity in tumor samples based on their expression profiles. Typically, transcriptomic data 
for tumor samples are provided as either relative expression or absolute values dependent the platforms used 
for generating the data. When two channel microarray platforms are used, the resulting data represent relative 
expression of genes with respect to a reference sample. In contrast, one channel microarray and RNA-seq 
platforms generate absolute expression level of genes. In this case, we convert data into relative expression via 
median normalization.
Providing the relative gene expression profile for a tumor sample, we rank genes based on their expression 
and summarize the baseline expression of genes by referring to their weights in the BRCAness profile, result-
ing in a BRCA score which is a quantitative measure of HR pathway activity. The underlying rationale is that 
in BRCA-like samples highly expressed genes (i.e., those with greater positive or negative relative expression 
values) tend to have higher weights in the BRCAness profile (W+ and W−), while the opposite is true for the 
non-BRCA-like samples. This form of correlation is nonlinear and is sensitive to genes distributed at the two 
ends of the sorted tumor gene expression profile. A rank-based statistical algorithm called BASE31, which is 
designed specifically to measure this correlation pattern, is applied to calculate BRCA scores in tumor samples. 
Briefly, genes are sorted into a ranked gene list based on their relative expression, and the biased distribution of 
BRCAness-upregulated (with high values in W+) and downregulated (with high values in W−) genes in this list 
were examined to obtain two scores, BS+ and BS−, respectively. The BRCA score is defined as their difference, 
BS+ − BS−. A higher BRCA score indicates high likelihood of BRCAness and thereby lower HR pathway activity. 
Conversely, a lower BRCA score indicates less likelihood of BRCAness and thereby higher HR pathway activity. 
A similar statistical framework has been applied to integrate cancer gene expression data with gene knockdown 
profiles with detailed description available from Wang et al.30. The calculated BRCA scores were highly consistent 
with each other using BRCA1-, BRCA2- and BRCA1/2-based BRCAness profiles in all datasets we applied in our 
analyses (Supplementary Fig. S8).
Pathway enrichment analysis. According to the weights in the BRCAness profiles generated by com-
paring familial versus sporadic breast cancer samples, we selected 300 genes with the highest positive weights 
as the genes up-regulated in familial tumors. Similarly, three hundred down-regulated genes in familial tum-
ors were selected with the highest negative weights. Pathway enrichment analysis was performed based on the 
REACTOME database68. Hypergeometric test was used to calculate the p-value. Adjusted p-value was calculated 
by Benjamini and Hochberg method. All analyses were performed in R.
Associate BRCA scores with patient prognosis in breast and ovarian cancer. We applied 
Kaplan-Meier method to compare the survival times of patients in different groups. A log-rank test P-value was 
calculated to estimate the difference. Median of BRCA scores was applied as a threshold to divide patients into 
low and high BRCA score groups. The Cox proportional regression model was used to evaluate the individual 
contribution of BRCA scores to predicting survival in addition to the other clinical variables including age, ER 
status, Her2 status, tumor stage and tumor grade. Survival analysis was performed with the R package “survival”.
Correlate BRCA scores with genomic features. Using the gene expression profiles of TCGA breast 
cancer samples, we calculated a BRCA score for each sample. Because of the calculated BRCA score infers HR 
pathway activity, we focused on the genomic features of 27 HR genes that explains the majority of the correla-
tion between BRCA score and genomic features including CNV, DNA methylation, and gene expression. First, 
we ranked TCGA breast cancer patients based on their BRCA scores in decreasing order. For CNV and gene 
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expression, we compared the difference between that in top ranked (from 1% to 20%) patients and the remaining 
ones for each 27 HR genes. For DNA methylation profile, we first used the average beta value of CpGs in the 
promoter (from −2k to 2k of transcription start site) of a gene to represent this gene. Then, we compared the 
difference between that in top ranked (from 1% to 20%) patients and the remaining ones for each 27 HR genes. 
The Mann-Whitney-Wilcoxon Test was applied to calculate the difference. The calculations of CVN burden and 
mutation burden were same with our previously study30.
Associate BRCA scores with patient responsiveness to neoadjuvant chemotherapy. We used 
random forest69 models to predict pCR and RD patients in the Hatzis dataset. We only considered clinical var-
iables such as age, ER status, PR status, HER2 status, tumor grade, tumor stage, node information as predictors 
in the one model. In the other models, we combined the BRCA scores calculated using BRCA1-, BRCA2- and 
BRCA1/2-based profiles with those clinical predictors. The accuracy of prediction was investigated by calculating 
the AUC scores with 10-fold cross validation. The average and standard deviation of AUC scores were calculated 
to show the accuracy. The R package “randomForest” was used to perform these analyses. Moreover, R function 
“quantile” was utilized to divide patients into three groups.
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